An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Study sponsor: Ionis Pharmaceuticals, Inc. · IONS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-08Estimated
Enrollment · participants1400Estimated
Source updated2026-04-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.